about
Use of intravenous immunoglobulin in pediatric practiceFirst do no harm: uterine natural killer (NK) cells in assisted reproductionRisk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization StatementEffects of antepartum therapy for fetal alloimmune thrombocytopenia on maternal lifestyle.How we manage immune thrombocytopenia in the elderly.A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia.II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.Recurrent and Sustained Viral Infections in Primary Immunodeficiencies.Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency.Workshop on use of intravenous immunoglobulin in hand, foot and mouth disease in Southeast Asia.Transfusion and component characteristics are not associated with allergic transfusion reactions to apheresis platelets.Cetuximab-induced aseptic meningitis: case report and review of a rare adverse event.Cardiac rhythm abnormalities during intravenous immunoglobulin G(IVIG) infusion in two newborn infants: coincidence or association?Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases.Subcutaneous IgG in neurologic diseases.Pulmonary manifestations of primary immunodeficiency disorders in childrenImmunoglobulin replacement therapy for primary immunodeficiencies.Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.Prediction of nonresponsiveness to medium-dose intravenous immunoglobulin (1 g/kg) treatment: an effective and safe schedule of acute treatment for Kawasaki disease.Antibody replacement therapy in primary antibody deficiencies and iatrogenic hypogammaglobulinemia.Hyponatraemia in Guillain-Barré syndrome revisited.Managing patients with side effects and adverse events to immunoglobulin therapy.Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.Immune Gamma Globulin Therapeutic Indications in Immune Deficiency and Autoimmunity.Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion.Intravenous immunoglobulin: pharmacological properties and use in polyneuropathies.Periodontal and other oral manifestations of immunodeficiency diseases.Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.A novel BTK gene mutation, c.82delC (p.Arg28 Alafs*5), in a Korean family with X-linked agammaglobulinemiaA Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency.Safety of intravenous immunoglobulin and plasma exchange in critically ill patients.Successful hematopoietic cell transplantation in a patient with X-linked agammaglobulinemia and acute myeloid leukemia.Immune globulins and same-day thrombotic events as recorded in a large health care database during 2008 to 2012.Occurrence of hemolytic reactions on the same day as immune globulin product administrations during 2008 to 2014.Bilateral uveitis following intravenous immunoglobulin administration.Centrifugation-free washing: A novel approach for removing IgA from stored red blood cells.Clinical and economic outcomes of a "high-touch" clinical management program for intravenous immunoglobulin therapy.The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study.Tolerability and safety of the intravenous immunoglobulin octagam(®) 10% in patients with immune thrombocytopenia: a post-authorisation safety analysis of two non-interventional phase IV trials.IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety.
P2860
Q27011481-5B185F38-27BC-494F-88CA-98F3DACE56C8Q28083516-F475A413-6DDB-4D46-B403-0F1CA0CE004DQ30371972-5DCD8AA7-CA38-4FD2-B782-16E2AED551A6Q33424089-6220D2D1-5FC8-48B2-B118-E3D633551C5BQ33431371-6B2D19F2-7EB0-4E30-A255-2C0A94AD7B3FQ33442065-2958130B-D3EA-4A7A-BD20-D13A97D5C346Q33692418-A941B02D-5B04-485A-9FDA-A56D73D51BEAQ33809611-3DBA326C-4FBF-4ED7-B3BB-6590040AC151Q33843992-70693989-731E-4318-8802-0FAB8FF09808Q34844126-07007CEB-23AA-4E89-9124-892034176C3BQ35091355-0684469F-3470-406F-AD84-950EF623742DQ36067900-71FB07C5-3538-4961-B4A1-59286243098CQ36072369-44A57241-4F5C-45D8-8F4F-81C4061D68F7Q37254849-9FBC9946-FA06-4D5F-B368-A91ECF44367DQ38171572-6394457F-A0C4-40C1-8C00-BB411366727EQ38239698-AFF6D80D-67B3-44BC-B18F-84FC46221791Q38257643-9ED67666-ACA2-4BF6-898D-783D73FE13EFQ38266635-A99A99F5-BDEA-4107-943B-4B30F9ACCDB1Q38414480-05217E59-E4F9-4059-895D-75B3689F42D0Q38548417-E3823639-0476-4973-AD00-B778A46A756BQ38548955-4A604F72-7F6F-45E4-9097-E6864449D515Q38614953-1A8E57C2-A1A3-4737-9E55-AAED6975C306Q38729214-744CFB3A-A0A5-4D67-8D89-128B16D70E56Q38842992-CE175603-ACDC-4863-B72B-DF3361F0AD38Q38896505-89253DA3-9A9E-4636-B271-5907F9FAB621Q38900642-A85A03DC-EC17-49E1-A928-3E8587942729Q38954801-92B6DEBD-1503-4448-BEC1-62E36E2D4116Q39370917-B84CF348-31C8-42D7-902F-CA54D30C4385Q39677024-2573674A-1397-4E4C-98FC-129980748C4DQ40133456-050DA704-F6E6-4830-82FC-4A39F58A2453Q41442958-F962FA87-7972-4515-9159-9CC42089BB02Q42769181-6BA5272D-674A-42D2-8496-602E7AA2A055Q44589181-49903910-0ED4-4A01-8A4B-657B26440A4BQ45072412-958B1C0C-D2D2-4A41-A821-DBDE0D8F6D42Q47108804-7576A983-299A-4A38-AE22-2F5F5539E6F1Q47212997-74B19053-A456-4DE2-952D-EFF09E6EAB0AQ47217747-4FF603A0-2553-46D5-9C0D-4394EA080D34Q47673920-4FBE95BD-9EE3-42E8-B8CC-55695564D268Q47819163-0F89EB08-64BA-48A3-8D34-33ACE89EF9BFQ49299297-BE53AA29-1436-4EA8-8744-3E0DEA40252D
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Adverse effects of human immunoglobulin therapy.
@en
type
label
Adverse effects of human immunoglobulin therapy.
@en
prefLabel
Adverse effects of human immunoglobulin therapy.
@en
P1476
Adverse effects of human immunoglobulin therapy.
@en
P2093
E Richard Stiehm
P304
P356
10.1016/J.TMRV.2013.05.004
P577
2013-07-06T00:00:00Z